JK07

Asset

Neuregulin fusion protein selectively activates ERBB4 while blocking ERBB3, promoting cardiac repair and function.

Stage
Phase 2
Modality
Protein or enzyme
Target
Not known
2
Indications
4
Trials
1
Developer

Trial NCT06369298 is still running. Trial NCT06369298 updated in its registry on May 22, 2026. clinicaltrials.gov

Indications

2

In the full profile

  • Owner and partners1
  • Trials4
  • Competitors3

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets